Heat shock protein expression and release is closely associated with immunogenic forms of cell death. We show that activation of the stress response within tumor cells during cell death, using an engineered form of the heat shock transcription factor, leads to an immunogenic death. Cells dying through 'stressful death' show decreased phagocytosis by macrophages in vitro. Moreover, cells expressing heat shock proteins during cell death are significantly more protective against subsequent tumor challenge. These data demonstrate the utility of activating cellular stress programs over the course of cytotoxic therapies to enhance immune responses to dying cells.
Introduction
One of the key elements of immune regulation permits the immune system to distinguish antigens derived from normal cells dying through homeostatic processes, from those associated with pathological events. Although antigen-presenting cells can efficiently present antigens derived from apoptotic cells in vitro, 1,2 phagocytosis of apoptotic cells has been shown to cause release of immunosuppressive factors, [3] [4] [5] which may maintain immunological ignorance of peripheral antigens. Perturbation of the clearance of apoptotic cells can thus change the balance of immune regulation to stimulate effective immune responses. 3, 6, 7 Previous data from our laboratory indicated that the manner in which tumor cells die strongly influences the immunogenicity of the tumor. 8 As opposed to apoptotic death, enforced nonapoptotic death in murine tumor cells results in expression of Hsp70 and enhanced immunogenicity in vivo. 8 This expression of heat shock proteins is a critical component of the observed immunogenicity. 3, 8, 9 Expression of a number of heat shock proteins during the heat shock response is controlled by the heat shock transcription factor (HSF-1). 10 A deletion mutant of the HSF-1 transcription factor lacking negative regulatory domains, and thus constitutively active, has been defined and can directly mediate heat shock protein gene expression in target cells. 11 We demonstrate that expression of the constitutively active HSF-1 transcription factor leads to heat shock protein overexpression, but does not influence tumor death in vitro. However, expression of heat shock proteins during tumor cell death inhibits macrophage phagocytosis of apoptotic cells in vitro. Importantly, this expression of heat shock proteins during tumor cell death in vivo correlates with enhanced tumor immunogenicity.
Results
Expression of an engineered HSF-1 induces expression of heat shock proteins Previous data from our laboratory have demonstrated that overexpression of Hsp70 in tumor cells renders the tumor more immunogenic in vivo. 8, 9 We hypothesized that expression of an array of heat shock proteins at physiological levels would similarly affect tumor immune responses. To achieve this, we transfected CMT93 cells with a constitutively active deletion mutant of the heat shock transcription factor 11 or empty vector and selected neomycin-resistant clones. Western blotting of CMT93 clones expressing the constitutively active HSF-1 or control CMT93 clones expressing only the antibiotic resistance gene, demonstrated transgene-mediated expression of HSF-1 corresponding with upregulation of the immunogenic heat shock proteins Hsp70 and Hsp60, but no change in the constitutive heat shock protein Hsc70 (Figure 1 ). The induced heat shock proteins were functional as CMT93HSF1 cells were protected against treatment with a lethal heat shock at similar levels to control CMT93neo cells that had been preconditioned to induce heat shock protein gene expression (Figure 1b) . Expression of heat shock proteins has been described to decrease the sensitivity of cells to apoptotic stimuli.
When tested for sensitivity to apoptosis stimulated by the drug staurosporine, CMT93HSF1 displayed identical kinetics of apoptosis as control CMT93neo cells ( Figure  1d ). In addition, these cells were tested for expression of a range of apoptosis-regulatory bcl-2 family members by ribonuclease protection assay. CMT93HSF1 cells do not alter their expression of any of the regulatory molecules studied (not shown).
Expression of heat shock proteins in tumor cells undergoing apoptosis inhibits macrophage phagocytosis.
To develop models of in vivo apoptosis, CMT93HSF1 and CMT93neo cells were stably infected with retrovirus encoding HSVtk and the selectable marker puromycin and clones selected. The enzyme HSVtk, with the help of cellular enzymes, converts the prodrug ganciclovir (GCV) into a toxic metabolite resulting in death of cells expressing the HSVtk transgene. CMT93HSF1 HSVtk clones maintain expression of heat shock proteins ( Figure  2a) , and display identical growth properties and sensitivity to GCV as control CMT93neoHSVtk cells ( Figure  2b ). Previous data from our laboratory indicated that the presence of exogenous heat shock proteins could inhibit the phagocytosis of apoptotic cells by macrophage cell lines. 3 We investigated whether physiological levels of heat shock protein upregulation in tumor cells undergoing apoptosis could have a similar effect on more relevant fresh peritoneal macrophages. Fresh peritoneal macrophages derived from GFP transgenic mice were cocultured with orange-stained CMT93HSF1HSVtk or control CMT93neoHSVtk cells for 48 h in the presence or absence of GCV. FACScan analysis of the combined cell population indicates fewer tumor cells expressing HSF-1 enter the GFP þ population on treatment with GCV (21%) than control tumor cells (40%) (Figure 2c ), indicating reduced phagocytosis of apoptotic cells by peritoneal macrophages in the presence of heat shock proteins. To confirm the identity of the phagocytic cells, the same experiment was performed using macrophages from nontransgenic mice and following coculture, the combined population was stained with FITC-conjugated antibodies to MHC class II. Again fewer tumor cells expressing HSF-1 enter the MHC II þ population when treated with GCV (53%) than control cells (69%) (Figure 2d ). Thus, expression of heat shock proteins during cell killing limits the phagocytosis of apoptotic cells by macrophages.
Expression of constitutively active HSF-1 renders CMT93 tumors more immunogenic in vivo
We next determined whether enforced expression of heat shock proteins in the CMT93 tumor that does not express 
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Mice vaccinated with live tumors expressing HSF-1 followed by surgical excision display significantly decreased tumor development compared to naïve mice or mice similarly vaccinated with control CMT93neo cells (Po0.05) (Figure 3a) . We observed no difference in the mode, or levels of cell death, between the parental or Hsp70-expressing tumor cell lines. We believe that the effects observed in this figure represent the results of the presence of Hsp70 during cell death in vivo as a result of cells dying during normal progression of tumor growth. Thus, Hsp70 affects the response of host immune effector cells at the tumor site, consistent with our previous findings reported in Gough et al 3 by decreasing the amount of phagocytosis affected by macrophages which would otherwise remove apoptotic cell debris and by altering the profile of cytokine expression from these macrophages from immunosuppressive (mainly IL-10) to immunostimulatory (mainly TNF). 3 To extend these observations to a model of in vivo apoptosis, mice were injected with live CMT93HSF1HSVtk or control CMT93neoHSVtk into the peritoneal cavity. This site was selected for the large phagocyte population that could be influenced by modification of in vivo apoptosis. Tumors were allowed to establish for 5 days, then tumors were destroyed in vivo with five daily i.p. injections of GCV. At 3 weeks following the last GCV injection, mice were rechallenged with s.c. injection of parental CMT93 cells, and tumor development monitored. Figure 3b demonstrates that mice receiving CMT93HSF1HSVtk were protected significantly more against tumor development than naïve mice or control mice receiving CMT93neoHSVtk (Po0.05). These data demonstrate that expression of heat shock proteins renders the tumor significantly more immunogenic in vivo.
Discussion
These data demonstrate that colorectal tumor cells can be modified to functionally overexpress several different heat shock proteins, by delivering a single engineered transcription factor. Overexpression of these heat shock proteins does not affect the sensitivity of these cells to apoptosis, but cells overexpressing heat shock proteins during cell death are phagocytosed less readily by macrophages in vitro. This decreased phagocytosis is also associated with increased immunogenicity of the tumor. The increased immunogenicity of tumor cells overexpressing heat shock proteins is most noticeable when tumor cells are killed in vivo in the peritoneal cavity -in the presence of large numbers of phagocytes.
The potential for secondary necrosis in apoptotic cells that are not phagocytosed could provide a further explanation for the immunogenicity of nonapoptotic and heat shock protein-associated 'stressful' cell death. We have previously shown that tumor cells killed via apoptotic mechanisms are rapidly phagocytosed by macrophages and cause secretion of the antiinflammatory cytokines IL-10 and TGF-b. 3 In contrast, cells that are modified to die via nonapoptotic pathways are less rapidly phagocytosed and cause secretion of proinflammatory cytokines. This modulation of the macrophage response was shown to be due in part to the presence of Hsp70 in cells dying via nonapoptotic mechanisms, and addition of exogenous Hsp70 blocked macrophage phagocytosis and the associated secretion of antiinflammatory cytokines. 3 We hypothesize that the reduced phagocytosis by macrophages and increased level of secondary necrosis in the apoptotic population, leads to enhanced release of antigen and endogenous adjuvant present in necrotic cells 13 for uptake by dendritic cells. Additionally, the expressed heat shock proteins function both as additional adjuvant 14, 15 and efficiently chaperone tumor antigens to antigen-presenting cells. [16] [17] [18] The relative importance of these distinct facets of heat shock protein activity may relate to the receptor molecules utilized by released heat shock proteins. Thus, heat shock proteins binding to CD14 14 or Toll-like receptors 15 may function to enhance innate immunity via antigenpresenting cell activation. In contrast, heat shock proteins binding to CD91 19, 20 may interfere with phagocytosis of apoptotic cells. [21] [22] [23] In such a model, the result of heat 6 CMT93neoHSVtk or CMT93HSF1HSVtk i.p. on day 0, then treated with 80 mg/kg GCV i.p. over days 5-9. These mice, along with untreated naïve mice were rechallenged with 2 Â 10 6 parental CMT93 s.c., and tumor growth followed for 60 days. Kaplan-Meier plot shows survival as tumor-free mice (ie mice that develop no measurable tumors): CMT93neo -squares; CMT93HSF-1 -circles; naïve -diamond. In total, 10 mice per group.
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shock protein release will depend on the cell types and receptor expression in the immediate vicinity of the dying cells. 24 Together these effects could explain the increased immunogenicity of tumor cells undergoing a 'stressful death' in vivo.
The engineered HSF-1 transcription factor described in these experiments provides upregulation of a panel of heat shock protein genes through delivery of a single transgene. We have concentrated on Hsp70 as a heat shock protein that is tightly induced in murine cells in response to heat shock and nonapoptotic cell death 8 and enhances tumor immunogenicity. 8, 9 However, HSF-1 increases expression of a number of heat shock proteins, and multiple heat shock proteins have displayed similar efficacy in models of chaperoning antigen and adjuvant activity. 14, 15, 25, 26 The selection of transcription factors for gene therapy has a number of advantages over delivery of individual downstream genes. Of particular advantage is that transcription factor delivery overcomes the technical limitations of delivery of multiple genes using multiple transcriptional elements and the genome size limit inherent in the majority of available vector systems. This is especially relevant in view of recent data indicating that multiple heat shock proteins provide greater adjuvant function to apoptotic cells than individual heat shock proteins. 26 We show here that existing gene therapies can be modified to render their cytotoxicity significantly more immunogenic, which has important implications for the design of cytotoxic therapies that optimally combine cytoreduction and immune activation.
Materials and methods

Reagents and cells
The pCDNA3.1 expression construct containing a constitutively active HSF-1 deletion mutant HSF-1 d202-316 , 11 the pBabePuro and pBabeHSVtk constructs 8 
Western blotting
For analysis of protein expression, cells were lysed in 20 mM Tris-HCl (pH 7.5). containing 1% Triton X-100, 0.05% SDS, 5 mg/ml sodium deoxycholate and 150 mM NaCl, centrifuged at 13 000 r.p.m. for 30 min at 41C, and the supernatant retained. Protein assay was performed using a protein assay dye reagent (Biorad, Hercules, CA, USA). Each sample was denatured, then electrophoresed on a 10% Tris-HCl gel along with Kalidoscope prestained molecular weight markers (Biorad) until resolved. Gels were transferred semidry to Hybond ECL nitrocellulose membranes (Amersham Pharmacia Biotech). Nonspecific binding was blocked with 10% milk in TBS-T (TBS plus 0.05% Tween-20), and blots were probed with specific antibody diluted 1% milk in TBS-T. Probed blots were washed and incubated with detection antibody (antispecies-HRP) in TBS-T. Binding was detected using a SuperSignal West Pico Chemiluminescent Substrate kit (Pierce, Rockford, IL, USA) and exposed to film. To strip blots of antibody complexes for reprobing, blots were treated with 7 M guanidine, then rinsed in TBS-T and reblocked with 10% milk in TBS-T. Where appropriate, for quantitation, films were scanned and band intensities calculated using the public domain NIH Image program.
Thermotolerance assay
To test whether HSF-1 expression was functional in protecting cells from lethal heat shock, cells in culture flasks were heat shocked at 451C for 45 min, then returned to culture at 371C. As a control, cells not expressing HSF-1 were preconditioned to activate protective heat shock protein expression by exposure to 421C for 20 min, then returned to culture for 6 h. These cells were then exposed to lethal heat shock along with other samples. At 48 h following lethal heat shock viable cells were counted by trypan blue exclusion.
Apoptosis and proliferation assays
To test the sensitivity of cells expressing HSF-1 to apoptotic stimuli, cultures were exposed to 100 nM staurosporine (Sigma) for 6, 12 or 24 h prior to apoptosis assay using an Annexin-V-Fluos Staining Kit (Roche, Indianapolis, IN, USA) and Flow cytometry. Gates were constructed for live (FITC À PI À ), apoptotic (FITC þ PI À ) and necrotic (FITC þ PI þ ) cells. To test the kinetics of tumor cell death through expression of HSVtk with and without HSF-1, cells were seeded in triplicate into 96-well plates at 1 Â 10 4 cells/ well, with or without 5 mg/ml GCV. At 0, 24, 48 and 72 h, 10 ml MTT reagent (Roche, Indianapolis, IN, USA) was added to cells for 1 h, then cells were lysed with 100 ml MTT lysis reagent and incubated overnight. The absorbance of each well was read at 550 nm.
In vivo tumorigenesis and vaccination experiments
All procedures involving animals were approved by and performed according to the guidelines of the Institutional Animal Care and Use Committee of the Mayo Foundation. Subcutaneous challenge and rechallenge models were performed as previously described. 8 In vitro and in vivo phagocytosis assay For in vitro phagocytosis assays, peritoneal macrophages were harvested from euthanized naïve C57BL/6 mice. Peritoneal cells were washed and 5 Â 10 5 cells combined with 1 Â 10 5 Cell Tracker Orange (Molecular Probes, Eugene, OR, USA) stained tumor cells, 5 mg/ml GCV was added to appropriate wells, and cultures incubated for 48 h before assay. Following cell harvest, cocultures were stained with I-A b -FITC to distinguish the MHC class IIexpressing macrophages. In one experiment, the same coculture was performed with peritoneal macrophages from C57BL/6 mice transgenic for GFP (C57BL/6-TgN(ACTbEGFP)1Osb, Jackson Labs, Bar Harbor, ME, USA). Cocultures were analyzed by flow cytometry.
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